Trials / Active Not Recruiting
Active Not RecruitingNCT04632108
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors. Patients with gastric cancer/gastroesophageal junction adenocarcinoma and pancreatic cancer are preferred.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ASKB589 Injection | ASKB589 Injection with dose escalation stage of 0.3mg/kg up to 20mg/kg,as well as dose expansion stage with recommended dose level from dose escalation stage. |
Timeline
- Start date
- 2021-01-28
- Primary completion
- 2025-10-31
- Completion
- 2025-12-31
- First posted
- 2020-11-17
- Last updated
- 2025-09-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04632108. Inclusion in this directory is not an endorsement.